How to approach castration-resistant prostate cancer?

Abstract

The therapeutic landscape of castration-resistant prostatecancer (CRPC) has changed dramatically in the last decade.Previously, limited to castration, second-line hormonalmanipulations, and palliative treatment with mitoxantroneplus prednisone, median overall survival (OS) remainedin the 9-18 months range. With multiple lines of survivalimproving chemotherapies, AR-directed drugs, as well asnew immunotherapy and bone-directed therapies, medianOS increased to more than 30 months and quality of lifeincreased accordingly. The question remains, as how tosequence, and choose the best therapeutic option for eachindividual patient with the current data.Keywords: Prostatic neoplasms, Castration-resistant,Immunotherapy, Chemotherapy, Antineoplastic agents,Hormonal, Radioimmunotherapy